FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

NCT04832776 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Liver Metastasis Colon Cancer

Interventions

DRUG: Cetuximab
DRUG: Bevacizumab
DRUG: FOLFOXIRI

Sponsor

Fudan University